MedTrace Logo

The Phase I Study of Recombinant Human Nerve Growth Factor Injection

NCT04232332 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2021-08-17

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and pharmacokinetics

Conditions

  • Injury of Optic Nerve

Interventions

DRUG

Recombinant human nerve growth factor injection,experimental

Intramuscular injection once on the first day according to dose requirements

DRUG

Recombinant human nerve growth factor injection,single dose

Intramuscular injection once on the first day according to dose requirements

DRUG

Recombinant human nerve growth factor injection,multiple dose

Intramuscular injection once daily for 7 days according to dose requirements

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Xiuli Zhao · Beijing Tongren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-26
Primary Completion
2021-12-31
Completion
2022-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232332 on ClinicalTrials.gov